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Summary 
Although  microglia are the only cells found to be productively infected in the central nervous 
system  of acquired  immunodeficiency  disease  syndrome  (AIDS)  patients,  there  is  extensive 
white and gray matter disease nonetheless.  This neuropathogenesis  is believed to be due to in- 
direct mechanisms other than infection with human  immunodeficiency virus 1  (HIV-1).  Cy- 
tokines  and  toxic  small  molecules  have been  implicated  in  the  clinical  and  histopathological 
findings in CNS AIDS. Previously, we have demonstrated in rodent glial cultures the presence 
of biologically active epitopes ofgpl20 and gp41 that are capable of inducing interleukin  1 and 
tumor necrosis factor ix. In this study, we map the HIV-1  envelope epitopes that induce nitric 
oxide, inducible nitric oxide synthase, interleukin  1, and tumor necrosis factor ix in human glial 
cultures.  Epitopes  in the  carboxy terminus  of gp120  and the  amino  terminus  of gp41  induce 
these  proinflammatory  entities.  In  addition,  we  compare  HIV-1  infection  and  pathology  in 
glial cells derived from human brain taken at different states of maturation  (fetal, neonatal,  and 
adult brain) in an effort to address some of the clinical and histological differences seen in vivo. 
This study demonstrates that, in the absence of virus infection and even in the absence of dis- 
tinct  viral  tropism,  human  glia  respond  like  rodent  glia  to  non-CD4-binding  epitopes  of 
gp120/gp41  with cytokine and nitric oxide production.  Differences among fetal, neonatal, and 
adult glial cells' infectivity and cytokine production  indicate that, in addition to functional dif- 
ferences  of glia at different  stages of development,  cofactors in vitro and in vivo may also be 
critical in facilitating the biological responses of these cells to HIV-1. 
H 
IV-1  disease  produces  a  primary  neurologic/neuro- 
psychiatric  disorder,  although  the  precise  contribu- 
tion of virus to either brain or spinal cord pathology or to 
clinical symptoms is thought not to be due to actual infec- 
tion  of neurons  or oligodendrocytes  (1).  Infection  in fetal 
brain is difficult to detect  even by PCk  or in situ  hybrid- 
ization,  and virus isolation from these brains is rare.  When 
infection  occurs in  fetal brain,  it does  so in  few cells and 
may  be  latent  or  defective  (2).  HIV-1  nucleic  acids  and 
proteins  are more  easily detected  in pediatric  than  in fetal 
brain; nevertheless, infection in neonatal brain is at a lower 
level  than  in  adult  brain,  and  productive  infection  is  not 
usually evident (3). 
Because  pathology  occurs  in  cells  not  infected with  vi- 
res,  it  is possible that  cytokines  and  small toxic  molecules 
are  indirectly  at  work  in  central  nervous  system  (CNS) 1 
AIDS  (4).  In AIDS patients,  HIV-1  infection increases the 
levels  of several proinflammatory  cytokines,  such  as  IL-1, 
IL-6, and TNF-IX in vivo and in vitro  (for review see re- 
ference  4).  TNF-o~  and  IL-1  have  been  found  to  be  ele- 
vated in CNS  AIDS brain  tissue,  with  significantly higher 
amounts  in  demented  HIV-l-infected  patients  (5).  Levels 
of TNF-o~ have been  correlated  with  spinal cord vacuolar 
1Abbreviations used in this paper: ANOVA, analysis of variance; AZT, azi- 
dothymidine; CNS, central nervous system; CYTO, cytokines; GCT, gi- 
ant cell tumor supernatant; iNOS, inducible nitric oxide synthase; Dil-0t- 
LDL, acetylated low-density lipoprotein; mP,  NA, messenger RNA; NO, 
nitric oxide; NO~-, total nitric oxide; P,  CA-1, Ricinus communis aggluti- 
nin 1; WP,., wild type. 
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HIV-1  induction  of IL-1,  TNF-o~,  and  IL-6  in  macro- 
phages and glia are interesting since all three of these cyto- 
kines up-regulate HIV-1 replication in T  cells or MO  (1, 6). 
The primary cell type infected in vivo in CNS AIDS is 
the microglial cell (1). The CD4-independent infections in 
human astrocytes (malignant or primary fetal) were usually 
transient,  nonproductive/latent,  or  partially defective and 
did not lead to in vitro cytopathicity (7-9). In human adult 
brain, CD4*  macrophages were shown to fuse and die after 
in vitro infection by a  macrophage-tropic strain of HIV-1 
(10), but there is some controversy remaining as to whether 
human  microglia are CD4 +  and whether  they can be  in- 
fected (11,  12). 
Recently,  human  macrophages,  astrocytes, and  astrocy- 
tomas have been shown  to produce nitric oxide (NO)  via 
inducible  NO  synthase  (iNOS)  in  response  to  cytokines 
and  gp120  (13-16).  iNOS  has been  seen in AIDS  retina, 
suggesting NO  as a  possible mechanism for CNS  damage 
(17);  NO  damages neurons and oligodendrocytes in vitro. 
Because gp120 and gp41 are able to induce IL-1 and TNF-ot 
in glial cultures (18, 19), we have mapped epitopes in HIV-1 
envelope that induce IL-1, TNF-cx, and iNOS at the pro- 
tein and messenger 1KNA (mlKNA) level. In the absence of 
significant productive  infection,  gp120  carboxy  terminus 
and  gp41  amino  terminus  epitopes give rise  to  cytokines 
and  NO  production  in  human  glial  cultures  from  tissue 
taken at different stages of development. 
Materials  and Methods 
Primary Human  Glial  Cells: Establishment  of Cultures  and  Glial 
Cell Type Identification.  The  human  glial  cultures  were  estab- 
lished from adult, neonatal, and fetal brain tissue.  The adult and 
neonatal brain tissue  was obtained from epilepsy patients under- 
going surgical resections for intractable seizures. Tissues from four 
adults were obtained; the patients' average age was 23.8  -+ 4.0 yr 
(range  18.0-32.0  yr).  The  tissue  was  derived from  frontal and 
temporal lobe regions. The neonatal brain tissues were procured 
from 10 cases, with an average age of 3.1  +  2.0 yr (range 1.4-5.0 
yr). These tissues were mainly from temporal lobectomies. Entire 
brains of 10 aborted fetuses  were obtained from Advanced Bio- 
science Resources, Inc. (Alameda, CA). They were from fetuses 
19.8  +  1.8 wk old (range 17.5-24.0 wk). 
Human brain tissue was prepared as previously described (18) 
and cultured in Iscove's modified Dulbecco's medium (Irvine Sci- 
entific,  Santa Aria, CA) containing 10% non-heat-inactivated FCS 
(Gemini Bioproducts, Inc., Calabasas, CA) as well as L-glutamine 
(2 mM) and gentamicin sulfate  (50 !~g/ml), both purchased from 
lrvine Scientific. Once cultures were established (1-4 wk), they 
were  split at passage  1 and maintained in  two  variations of Is- 
cove's medium (see above) containing glial growth factors.  One 
medium contained 10% giant cell tumor supernatant (GCT; AIDS 
Research and Reference Reagent Program, Rockvitle, MD); this 
was used to duplicate culture conditions previously described for 
infection of human adult microglia (10).  A second medium (cy- 
tokines [CYTO])  contained known concentrations of microglial 
growth  factors:  M-CSF,  GM-CSF, and  IL-3  (each  used at 2.8 
ng/ml, Immunex Corp., Seattle, WA). 
For phenotyping, viable or fixed glial cells were stained as previ- 
ously described (18). Astrocytes were detected using a polyclonal 
antiglial fibrillary acidic protein antibody (1:100; Boehringer Mann- 
heim Corp., Indianapolis, IN). Microglia were labeled using mon- 
oclonat EBM-11  (anti-CD68,  I:50;  DAKO  Corp.,  Carpinteria, 
CA), fluorescein-conjugated Ridnus communis aggludnin 1 (RCA-I), 
1:50 (Vector Laboratories, Inc., Burlingame, CA), and, for recep- 
tors for acetylated low-density lipoprotein, 1 tzg/ml 1,1 '-dioctade- 
cyl-l-3,3,3'3'-tetramethyl  indocarbocyanine  perchlorate-conju- 
gated  LDL  (DiI-~-LDL)  (Biomedical  Technologies,  Inc,, 
Stoughton, MA). A proportion ofastrocytes also stains with RCA-1. 
Polyclonal Factor VIII antibody (1:50; DAKO Corp.) was used to 
detect endothelial cells. Staining for neurons was with anti-neuron- 
specific  enolase  (1:50;  DAKO  Corp.),  and for oligodendrocytes 
with polyclonal antibody to galactocerebroside (1:20,  Boehringer 
Mannheim Corp.). The major histocompatibility complex class II 
antigens were detected on astrocytes and microglia with an anti- 
HLA-DR antibody (1:50,  Becton Dickinson &  Co.,  Mountain 
View, CA). The presence of CD4 antigen on astrocytes and nil- 
croglia was  also assessed (1:100,  OKT4A;  Ortho Diagnostic Sys- 
tems,  Inc.,  Raritan,  NJ).  For pathological assessment,  cells were 
stained with  a buffered differential Wright's stain  (Camco  Quik 
Stain; Baxter Scientific Products, McGaw Park, IL). 
Preparation and  Quantitation  of Reconlbinant  env  Proteins from 
env:vaccinia Virus Infections.  Recombinant viruses were provided 
to us by Drs. Bernard Moss and Patricia Earl  (National Institutes 
of Health, Bethesda, MD).  These included six serial truncation 
mutants from the carboxy terminus of the full-length gp160 engi- 
neered into vaccinia virus and expressed in HeLa cells as previ- 
ously described (19).  Controls included medium alone and wild- 
type (WR) vaccinia virus-infected and mock-infected (medium 
alone) HeLa cells, vPE or WR virus titers were determined, stocks 
were prepared,  and  vPE  proteins were  quantitated on  Western 
blots  (19).  When  titered on  CV-1  or HeLa cells,  no  infectious 
vaccinia virus was detected in these vPE or WR supernatants. 
Treatment  of Glial  Cuhures  with  env  Proteins from  Recombinant 
Vaccinia  Viruses.  Glial cells at  10('/nil in  24-well plates (Falcon 
Labware, Becton  Dickinson &  Co.)  were preconditioned over- 
night with the serumless UltraCHO medium (BioWhittaker, Inc., 
Walkersville, MD) followed by exposure to medium alone or me- 
dium containing equivalent moles of recombinant vPE env pro- 
teins, WIK, or mock-infected control supernatants. To control for 
any effects  of vaccinia virus proteins, WR  control supernatants 
were added to glial cells for the same length of time and at a con- 
centration equal to the highest concentration of any of the vPE 
supernatants. After replacement of medium and an additional 2-h 
incubation, the glial cell supernatants were harvested. Theretbre, 
the time designated for glial cell supematant harvests  for IL-I and 
TNF-c~ is a total time of 4 h after initial exposure to env proteins 
or control supernatants. While other time points (8 h, 24 h) were 
examined, 4 h proved to be optimal. These gliat cell supernatants 
contained no HIV-1 or vaccinia virus proteins as determined by 
analysis of Western blots using anti-gp160 or anti-gp41 and anti- 
vaccinia virus. This is probably due to the fact that the glial cells 
were washed after their 2 h exposure to supernatants from Heka 
cells.  For NO  measurements,  the  incubation  of glial cells  with 
env proteins proceeded for  1 wk  before the  supernatants were 
harvested, which proved to be a peak production time point. 
Treatment of Glial  Cultures with Bacterially Produced Recombinant 
env  Proteins and  Heat-inactivated  HIV-I  Virus.  R.ecombinant 
HIV-1  env proteins (gp160,  gp120,  and gp41)  and the  control 
gag  protein  (p24)  produced  in  bacteria  were  purchased  from 
American BioTechnologies (Cambridge, MA) and used to stimu- 
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HIV-1NL4_  3 and HIVrqFN_SX were  gradient purified, heat inacti- 
vated at 65~  for 45 rain, and added to glial cells at a p24 concen- 
tration of 100 ng/ml. For total NO (NOx-) production and IL-1/ 
TNF-ot/iNOS Northern blot analyses, stimulation with IL-113 (5 
ng/ml)  plus IFN-',/ (70  ng/ml)  (both cytokines from Immunex 
Corp.) was used as a positive control. With recombinant env pro- 
teins and heat-inactivated HIV-1 strains,  stimulation of glial cells 
was performed for 4 h and 1 wk for assessment  of IL-1/TNF-ci 
and NO,  respectively. As a control for the bacterially expressed 
recombinant envelope proteins, the gag protein of HIV-1, p24, 
was used as a negative control for the production of NO. 
HIV- 1 Infection of Glial Cells.  Gradient-purified virus (18-20) 
from the T  cell-tropic strain of HIV-1  (NL4-3)  and the MO- 
tropic strains JR-FL and JR-CSF as well as a hybrid recombinant 
strain (NFN-SX) (18, 21)  were used to attempt to infect human 
glial cultures. Glial cultures and control PBLs at 106 cells/culture 
in media with GCT or cytokines were exposed to 104-105 infec- 
tious U  (300-500 ng/culture, p24 titer as measured by the HIV-1- 
specific ELISA [Abbott Laboratories, North Chicago, IL]). At this 
multiplicity of infection,  as  expected, maximal infection of the 
PBLs  with  the  virus occurred at  1 viral DNA  copy per  1,000 
cells. After exposure to virus, 10% of the total cells was assayed by 
PCR.  As fewer brain cells were  exposed to  virus,  the  relative 
amount  of virus  added  per  cell was  ~50-fold  higher  for  the 
brain-derived cells. In one experiment, tissue was processed into a 
glial cell suspension but was not cultured; rather,  this fresh cell 
suspension was placed in Iscove's medium (with no additive or 
with GCT or CYTO) and exposed to virus immediately. 
Endotoxin levels of all reagents were measured by the limulus 
amebocyte  lysate  assay  kit  (BioWhittaker,  Inc.,  Walkersville, 
MD).  Only those recombinant proteins, azidothymidine (AZT) 
or heat-inactivated viruses,  live viruses, vPE, WR, and HeLa su- 
pernatants  that  had  an  endotoxin  content  of ~<10 pg/ml were 
used to treat the glial cells (19). 
PCR Analysis of HIV-I  Entry and Infection in  Glial Cells.  At 
the times designated above, DNA was recovered and subjected to 
25  cycles of PCR  amplification according to  techniques  previ- 
ously described (18, 20).  Quantitation was accomplished by ana- 
lyzing in parallel a standard curve  of cloned HIV-1jR_cs F DNA 
linearized with EcoRl,  which  does not  cleave viral sequences. 
Entry of virus into cells was determined by choosing primer pairs 
for  PCR  that  detect initiation (primer pairs M667/AA55)  and 
completion (primer pairs M667/M661)  of reverse transcription. 
[~-globin DNA amplification was used as an internal control for 
the amount of DNA being amplified in glial cells (20). 
IL-1,  TNF-ee,  and NOx- Assays.  As previously described by 
this  laboratory,  IL-1  activity was  measured  using  the  LBRM 
331A5 conversion assay, and TNF-o~ was measured by cytotoxic- 
ity ofL929 cells (18). NO production was measured at day 3 and 
day 7 as described earlier. The nitrite (NO2-) plus nitrate (NO3-) 
determination yields total NO  levels and was  performed using 
boiling vanadium (III) with detection by means of chemilumines- 
cence (22, 23). 
Northern  Blot Analysis  of Cytokine  and  iNOS  mRNA.  The 
presence, regulation, or induction ofmRNA for IL-1 and TNF-o~ 
in glial ceils after env protein exposure was monitored by North- 
ern  blot  analysis.  Glial cells  were  incubated with  env  proteins 
from supernatants of vaccinia virus recombinants. As a positive 
control, cells were stimulated with IL-113 (5 ng/ml) plus IFN-y 
(70 ng/ml)  (both gifts from Immunex Corp.); the negative con- 
trols were WR infected, HeLa cell supernatant, or medium alone. 
The cell pellets were harvested after a 1-h and a 3-h exposure for 
cytokine mRNA and a  6-h exposure for iNOS mRNA.  Total 
RNA was isolated using previously published techniques (19). 
Human IL-113 mRNA was probed using a 1.05-kb PstI cDNA 
fragment contained in pBR322 vector. Human TNF-cl mRNA 
was  detected by  hybridization with  a  0.82-kb  EcoRI-digested 
cDNA  fragment  in  pUC  vector;  both  probes  were  purchased 
from American Type Culture Collection (Rockville, MD).  The 
human hepatocyte iNOS cDNA fragment of 2.1 kb was digested 
from pBluescript SK with EcoRI and BamHI (obtained from Dr. 
D. Geller, University of Pittsburgh, Pittsburgh, PA) (24). Probing 
with the cDNA for cyclophilin n~NA  was used as a control for 
the amount of total RNA loaded in each lane. mRNA was de- 
tected using a 0.7-kb BamHI cDNA fragment of rat cyclophilin 
gene,  isolated from pCD  vector (obtained from Dr. J.  G.  Sut- 
cliffe,  The  Scripps Research Institute, La Jolla, CA).  For cyto- 
kines and iNOS, the exposure was 6 to 9 d, while, for cyclophilin, 
exposure was  overnight.  For reprobing of the  same membrane 
with another cDNA, the membrane was stripped of the hybrid- 
ized probe with 0.1  ￿  SSC/0,1% SDS at boiling temperature for 
20 rain. The autoradiograms were quantitated using a laser densi- 
tometer  (Ultroscan  XL;  LKB  Instruments,  Inc.,  Gaithersburg, 
MD)  to estimate the levels of mRNA of genes that were tran- 
scribed. The  ratio of cytokine mRNA  induced by treated glial 
cells was compared with the mRNA levels of cyclophilin gene. 
Statistical Analysis.  The  levels of IL-1,  TNF-cq  and  NOx- 
produced by stimulation of gila were analyzed for significance by 
means  of a  multivariate  analysis  of variance  (ANOVA).  The 
paired Student's t test was performed comparing IL-1, TNF-cx, or 
NOx- activity in post facto analyses. 
Results 
Cellular  Composition  of  Human  Mixed  Glial  Cultures. 
Markers for cell identification in fetal, neonatal, and adult 
cultures grown in two types of medium are shown in Table 
1.  There  are no  significant numbers  of oligodendrocytes, 
endothelial cells,  or  neurons  in  these  cultures.  HLA-DR 
molecules were  seen predominantly on astrocytes and not 
microglia. CD4  molecules were  not present  on  fetal glia. 
We believe the minor population of CD4-positive cells in 
neonatal and adult brain cultures may be blood-borne mac- 
rophages  or  pefivascular  microglia  (also  blood-derived) 
contaminants and not parenchymal microglia. As enumer- 
ated by glial fibrillary acidic protein or e~-LDL, there were 
equal proportions of astrocytes and microglia, respectively, 
in  fetal,  neonatal,  and  adult mixed glial cultures whether 
they were cultured in CYTO  or GCT. Microglia were also 
identified  by  EBM-11  and  RCA-1.  EBM-11  identified 
fewer microglia than did cI-LDL in fetal and neonatal cul- 
tures and disappeared entirely from microglia in adult cul- 
tures.  RCA-1  identified  all  microglia  and  stained  up  to 
50%  of astrocytes in  fetal  and  neonatal  cultures,  but  not 
adult cultures (Table 1). 
Infection of and Pathology  in Human Mixed  Glial Cell Cul- 
ture  Exposed  to  HIV-1.  There  are  very  few  published 
studies on the infection of primary cultures of human glia, 
and the data are not always in agreement. Because of this, 
and because there is controversy as to the presence of CD4 
on microglia in vivo and in vitro and whether it is the gp120 
943  Koka et al. Table 1.  Human Mixed Glial Cultures: Cellular Composition; Percentage  of Positive Cells 
Fetal  Neonatal  Adult 
CeHma~er  CTYO  GCT  CYTO  GCT  CYTO  GCT 
n=8  n=9  n=4 
Astrocytes 
Glial fibfiUary 
acidic protein  40.5  -+ 5.1  59.2  +  15.1  55.5  -+ 7.1  43.6 -+ 7.3  40.0 +  10.3  50.5  -+ 3.8 
Microglia 
tx-LDL  54.0 -+ 15.3  37.5  4- 10.2  30.0 +  3.5  39.0 +  13.6  62.5  +  10.1  56.7  +  5.0 
EBM-11  29.3 -+ 25.0  16.7  +  16.1  18.3  +  3.5  11.3  4- 2.0  0 _+ 0  0.0 +  0.0 
P,  CA-1  58.3  -- 4.3  71.3  +  5.3  67.5  +  10.3  66.7  -  8.8  60.0  +  1.3  63.5  +  11.3 
Neurons 
NSE  0 +  0  0 -4- 0  6.7 +  6.5  0 -+ 0  0 +  0  0.0 --- 0.0 
Oligodendrocytes 
Galactocerebroside  2.0 _+ 2.0  0 +  0  0.4 4- 0.4  0 +  0  0 +  0  0.0 +- 0.0 
Endothelial cells 
FVIII  0 +  0  0 +  0  2.8 +  2.0  0 -  0  0 +  0  0.0 --+ 0.0 
Other 
HLA-DR.  15.6  -+ 5.0  4.3 +  4.0  11.1  +  3.5  6.0 +  2.7  26.7  --- 20.0  0.0 +  0.0 
CD4  0 --- 0  0 4- 0  4.0 +- 4.0  0 __- 0  6.7 +  5.1  5.0 +  5.0 
EBM-11,  CD68;  NSE, neuron-specific  enolase; FVIlI, factor VIII;  n, number of different brains cultured and stained; CYTO, IL-3, GM-CSF, 
M-CSF in Iscove's medium; GCT, 10% GCT in Iscove's medium. Means +  SD are shown. 
receptor in the brain, we have examined the entry of HIV-1 
into  glial cells using PCR  primers  specific for  either ini- 
tiation  (R/U5)  or  completion  of  reverse  transcription 
(LTR./gag). This was done to rule out incomplete infection 
of glial cells (20)  at 2,  3,  7,  and  12  d  after virus exposure. 
We  compared GCT  (a  "black box"  cocktail of cytokines)- 
grown cells to cells grown in a well-defined cytokine cock- 
tail (CYTO,  Table 1) that promotes survival and prolifera- 
tion of microglia. 
For PCR  analyses, infection with heat-inactivated virus 
was performed in parallel with live virus. This control pro- 
vides a background level for viral DNA  contaminating the 
virus  stocks.  This  contaminant  DNA  presumably  arises 
from lysis of virions from infected cells during preparation 
of the stock. Regardless of the excess amount of virus used 
to infect glial cells, there was relatively little infection com- 
pared with PBLs. HIV-1 strains NL4-3 andJR-CSF  never 
produced detectable infection over background in any cul- 
ture. The more macrophage-tropic HIV-1jR_FL and recom- 
binant NFN-SX strains produced an extremely low level of 
infection in four out of five fetal brains, using either fresh 
tissue  or  cultured  cells.  Cultured  fetal cells were  infected 
only minimally when  in the  GCT  medium  (Fig.  1 /3).  In 
contrast,  we  detected virus  only rarely in  neonatal  tissue 
(only twice in  10 different brain cultures)  and only if cells 
were in medium  containing IL-3,  GM-CSF, and  M-CSF 
(CYTO,  Fig.  1 B). Adult tissue, cultured either in CYTO 
or in GCT, was never detectably infected (Fig. 1 A, Table 
2).  The  positive infections  in  PBL  controls,  which  were 
analyzed within the first 20 h  of infection such that no virus 
spread could occur, produced HIV-1  copy numbers in the 
hundreds to thousands, indicating the highly infectious na- 
ture of the virus stocks (Fig. 1, Table 2).  Fresh preparations 
of fetal glial cells were infected at the same level as cultured 
fetal glia, suggesting that the culture conditions were not an 
explanation for low levels of HIV-1  infection. Similar data 
were  generated whether  RJU5  or LTR/gag primer pairs 
were  used.  When  infection occurred,  cultures were  posi- 
tive for infection by PCR. analysis at 72  h.  Culturing cells 
out to 12 d did not change these results (data not shown). 
In spite of the low level of infection, a certain amount of 
morphological change occurred in fetal cultures exposed to 
virus.  Fig. 2  demonstrates in vitro "pathology" in cultures 
that  were  not  productively  infected  with  the  NFN-SX 
strain.  GCT  cultures  displayed changes  that  were  some- 
what different from those in CYTO  cultures, in that GCT 
cultures  exposed  to  HIV-1  became  gliotic.  Astrocytes 
changed from an epitheloid to a spindly morphology (Fig. 
2,  days 2  and  12).  Large clumps of both microglia and as- 
troglia developed as determined by double staining (Fig. 2, 
days 2 and 12 and data not shown). The morphology of the 
mixed glia was  not  as dramatically altered in  CYTO  cul- 
tures  (e.g.,  not as much  gliosis). Nevertheless, monolayers 
did not grow in a  confluent manner  (Fig. 2,  day  12),  and 
944  HIV-1 env Induces IL-1, TNF, and NO in Human Glial Cultures Figure  1.  Quantitative PCIk analysis of HIV-1  infection of human glial cell DNA from human glial cell cultures exposed to live HIV-1NFN_SX. Cells 
were cultured with HIV-1  for 72 h  in the presence or absence of AZT, or they were cultured with heat-inactivated (H/) virus. Stimulated PBLs were 
used as a positive control. Control cells were harvested within 20 h of infection, before the time virus spread would occur, to indicate levels of infectious 
vires in the inoculum. As cultured cells were exposed to equal amounts of  virus and 10% of treated cells were analyzed, one would expect equal levels of 
viral DNA in brain versus PBL if the infectivity of the cells was identical. AZT has minimal effect on signals generated by the R/U5 primer pair since it 
does not significantly inhibit initiation of reverse transcription, as previously shown (20).  The primer pair M667/M661  specific for the LTR/gag region 
of HIV-13r~_r  which results in a 200-bp amplified DNA fragment, detects complete reverse transcripts. The DNA primer pair specific for the 1K/U5 re- 
gion of HIV-1jp,_FL, which results in a 140-bp amplified fragment, was used to detect initiation of  reverse transcripts. Use of the R/U5 primer pair is more 
sensitive than LTR/gag. The DNA standards used for HIV were cloned HIV-1jR.cs  r. (A) PCR analysis of HIV-1 infection of adult human glial cell cul- 
tures. There was no detectable level of infection of these cells with HIV-1NrN_SX. (B) PCIK analysis of HIV-1 infection of fetal and neonatal human glial 
cell cultures. Low-level HIV-1NrN_SX infection of neonatal glial cells  is detectable by both LTR/gag and R/U5  primer pairs. Arrow heads mark lanes 
with low but significant elevation in HIV-1 over heat-inactivated control lanes. 
Table  2.  Human Mixed Glial Cell Cultures: Infection with HIV- 1 Assessed by PCR 
Fetal  Neonatal  Adult 
Medium  CYTO  GCT  0  CTYO  GCT  CTYO  GCT 
n=5  n=lO  n=3 
Glia, fresh  0  10  10 
Glia, cultured  0  +-  0  7  +  5*  30  +  10~  0  +  0  0  +  0 
PBL  300  -+  100  450  -+  100  400  +  50 
0-0 
Data represent virion copies/106 cells. 
* Data represent the mean +- SD of all five brains where four positive infections occurred out of the five brain samples. 
SData represent the mean +  SD of the two positive infections of 10 brain samples. 
n, number of different brains cultured and exposed to HIV-1NFN_SX for PCIK analysis. R/U5  primer pair was used; CYTO, IL-3, GM-CSF, M-CSF 
in Iscove's medium; GCT,  10% GCT in Iscove's medium. 0, Iscove's medium without GCT or CYTO. Means -  SD are shown. 
945  Koka et al. Figure  2.  HIV-1 effects on human fetal mixed glial  cultures. Human fetal mixed glial  cultures containing 50% astrocytes and 50% microglia were ex- 
posed to five HIV-1NFN_SX.  This particular fetal brain, when cultured in GCT, did not yield a productive infection. The CYTO culture (IL-3, GM-CSF, 
M-CSF) was not productively infected. Parallel cultures without HIV-1 were also examined (control). Ceils  were stained with Cameo Quik stain, and 
photographs were taken (￿  at days  2, 7, and 12. 
microglia were increased in numbers in these cultures (Fig. 
2, day 7). 
IL-1  and  TNF-oe  Induction  in  Human  Mixed  Glial 
Cultures.  Neither  human  microglia  nor  astrocytes  pro- 
duce  as  much  IL-1  or  TNF-o/  when  cultured  as  isolated 
subsets as they do when cultured together, where they syn- 
ergize  to  produce  maximal  cytokines  (28,  29).  Because 
coculturing both  cell types is more relevant to  the  inflam- 
matory milieu in vivo, we did not separate them into sub- 
populations for induction of cytokines or NO.  Figs. 3  and 
4  demonstrate  that  HIV-1  env  proteins  and  heat  inacti- 
vated virus induce  IL-1  and TNF-o~ proteins and mP,  NA 
in human  glial cell cultures,  and that the  age of tissue and 
culture conditions make a  difference in  the amount  of cy- 
tokines induced. 
Fig. 3  demonstrates IL-1  and TNF-o~ production in cul- 
tured glia. In general, in  cultures with significant IL-1  in- 
duction, fetal cultures produced significantly more  IL-1  in 
response to vPE 16, -17, -20, and -21, and neonatal cultures 
produced significantly more IL-1 in response to vPE16, -17, 
and -21  in  CYTO  medium  than  in  GCT  medium.  Like- 
wise, fetal cells stimulated with  vPE17,  -18,  and -12  pro- 
duced significantly more  IL-1  in  GCT  medium than  neo- 
natal  cells.  Fetal  CYTO  cultures  produced  significantly 
more IL-1 in response to vPE16, -20, and -12 than did adult 
cells  and  to  vPE18,  -8,  and  -20  than  did  neonatal  ceils. 
Adult glia responded similarly whether in CYTO  or GCT 
medium.  After vPE16,  -17,  and  -18  stimulation  in  GCT 
medium,  adult glia produced significantly more  IL-1  than 
fetal cells. 
Compared  with  internal  controls  (medium,  HeLa,  or 
WR),  the  best  inducers  of  IL-I  in  fetal  and  neonatal 
CYTO  and  adult  GCT  cultures  were  vPE16  and/or  the 
heat-inactivated, M•-tropic  HIV-1  strain NFN-SX. In fe- 
tal  CYTO  cultures,  vPE16  was  significantly better  than 
vPE17,  -18,  -8,  -20,  -21,  and  -12  at  IL-1  induction.  In 
neonatal  CYTO  cultures,  vPE16  was  significantly better 
than  vPEt8,  -8,  -20,  -21,  and  -12.  No  such  differences 
were seen in  GCT  medium in fetal and neonatal cultures. 
In contrast, in adult cultures, no differences in any vPE in- 
duction  except  vPE21  were  seen  in  CYTO  medium, 
while, in GCT,  vPE16,  -17, -18,  and -12  induced signifi- 
cantly more IL-1  than  vPE8,  -20,  and -21  (Fig. 3).  vPE21 
induced the lowest levels of IL-1  in all cultures.  The  MQ- 
tropic strain was significantly better than  the  T  cell-tropic 
strain  at  IL-1  induction  in  fetal,  neonatal,  and  adult  cells 
cultured  in  CYTO.  Recombinant  gp41  induced  a  small 
but  significant IL-1  response  compared with  the  medium 
control. 
Fetal  and  neonatal  cells behaved  differently from  adult 
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glial  cultures (50%  astrocytes, 50%  microglia) from different ages  of hu- 
man brain tissue  grown under different conditions (GCT,  CYTO) were 
exposed to medium alone (MED), control vaccinia virus-infected HeLa 
cells  (WR), recombinant vaccinia virus  env proteins produced in  HeLa 
cells (vPE), a recombinant env protein produced in bacteria (gp41), and 
heat-inactivated, T  cell-tropic (NL4-3, NL) and MO-tropic (NFN-SX, 
SX) HIV-1 virions. Supernatants were harvested at 4 h  for assessment of 
ILl and TNFa production. Means -  SD are shown for different numbers 
of  brains cultured: fetal (n =  10), neonatal (n =  4), and adult (n =  4). IL-1 
responses were as follows. Fetal:  CYTO vs GCT:  vPE16, -17,  20, P  <~ 
0.01; fetal vs neonatal m GCT: vPE17, -  18, -  12, P ~< 0.01; fetal vs neo- 
natal  in  CYTO:  vPE18,  -8,  -20,  P  ~<  0.05;  fetal vs  adult  in  CYTO: 
vPE16, -18, -20, -12, P  ~< 0.05;  CYTO vPE16 vs vPE17, -18, -8, -20, 
-21, -12, P  ~  0.001;  CYTO SX vs NL, P  ~< 0.02.  Neonatal: CYTO vs 
GCT: vPE16, -17, -21, P  ~< 0.001;  CYTO vPE16 vs vPE18, -8, -20, 
-12, P ~< 0.01; CYTO SX vs NL, P <~ 0.02. Adult: adult vs fetal in GCT: 
vPE16, -17, -18, P ~< 0.01; adult vs neonatal in GCT: vPE16, -17, -18, 
-8, -12, -21, P ~< 0.001;  GCT vPE16, -17, -18, -12 vs vPE8, -20,  21, P ~< 
0.05;  CYTO SX vs NL, P ~< 0.01. All gp41, NL, SX vs MED, P <~ 0.01. 
All vPE vs WR,  P  ~< 0.001. All other comparisons were not significant. 
TNF-0t responses were as follows. Fetal: CYTO or GCT: vPE 16, -17, -18, 
-12 vs vPE8, -20, P ~< 0.01;  CYTO or GCT SX vs NL, P ~< 0.001. Neo- 
natal:  neonatal vs fetal or adult in CYTO  or GCT: vPE18,  -8, -21, P  ~< 
0.001;  GCT  vPE16,  -18  vs  vPE8,  -20,  -21,  P  ~<  0.01.  Adult:  GCT 
vPE16 vs vPE8, -20, -21,  P  ~<  0.01;  GCT vPE17 vs vPE20,  -21,  P  ~< 
0.05. The multivariate ANOVA and paired Student's t test analyses were 
used for statistical significance. 
cells  in  response  to  IL-1  induction  by  envelope  proteins 
given  that  CYTO  medium  allowed  for  more  IL-1  and 
TNF-r  production  than did GCT.  Adult cells did better in 
GCT  medium  than fetal or neonatal cells. Epitopes in gp41 
are  capable  of inducing  IL-1,  as  evidenced  by  stimulation 
with  recombinant  gp41  protein  and  by  the  power  of 
Figure 4.  Northern blot analysis oflL-1, TNF-ot, and iNOS mRNA in- 
duction in human fetal mixed glial cultures. Glial cells were incubated for 
1 h  or 3 h with stimuli for cytokine mR.NA and 6 h for iNOS ml<NA. 
Positive control were 5 ng/ml human IL-113 plus 70 ng/ml human IFN-y. 
Negative controls were medium alone or WP,-infected HeLa cell super- 
natants. Total  1<NA  at 30  p.g/Iane was electrophoresed. Blots were ex- 
posed to film 6 d for IL-115 and iNOS mRNA, 9 d for TNF-c~ mR.NA, 
and overnight for cyclophilin mRNA.  (A) Autoradiograms were quanti- 
fied by densitometry,  and  the ratio  of cytokine  mRNA  to  cyclophilin 
mRNA was  calculated.  (B)  As in A,  the ratio  of iNOS  to  cydophilin 
mRNA was calculated. 
vPE16  to induce  IL-1  better than truncation  vPEs with  de- 
letions  in  gp41.  Removal  of the  V3  loop  (vPE21)  signifi- 
cantly  reduced  IL-1  induction.  In  fetal  and  neonatal  cul- 
tures,  the  conformational  interaction  of  gp120  and  gp41 
may  be  important,  since  vPE12  (an  uncleavable  gpl60) 
gave a  significantly lower  IL-1  induction  than did vPE16. 
Fig. 3  also demonstrates the induction  of TNF-(x  in fetal, 
neonatal,  and  adult  glial  cultures.  In  contrast  to  medium/ 
cofactor-dependent  differences  seen  in  IL-1  induction 
(with  a  single  exception  of  fetal  in  GCT  induction  by 
NFN-SX),  TNF-(i  induction  was  the  same  in  GCT  and 
CYTO  medium  in  fetal,  neonatal,  and  adult  cultures.  In 
response  to  vPE18,  -8,  and  -21,  neonatal  glial  cells  pro- 
duced  significantly  more  TNF-oL  than  did  adult  or  fetal 
cells,  which  were  not  significantly  different  from  each 
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fetal  cultures  specifcally  produced  the  same  amount  of 
TNF-ot in response to heat-inactivated virus and recombi- 
nant gp41. 
In fetal cultures,  vPE16,  -17,  -18,  and -12  induced the 
same levels of TNF-ot but significantly more  than  was in- 
duced by vPE8  and -20,  which produced similar TNF-oc 
This suggests that gp41  is important and the V3 loop is not 
important in TNF-ot production. Likewise, in neonatal and 
adult cultures, removal of all gp41  epitopes (as in vPE8, -20, 
-21)  significantly reduced TNF-0~ in contrast to what was 
seen for IL-1. vPE21  did not induce significant TNF-o~ in 
any cultures. In contrast to IL-1 induction, gp41 stimulated 
as  much  TNF-o~  as  did vPE16  and  heat-inactivated virus 
induction.  These  data  suggest  a  more  important  role  for 
gp41  in TNF-~x than  IL-1  induction.  In fetal cultures,  the 
MO-tropic strain induced significantly more  TNF-o~ than 
did the T  cell-tropic strain; there was no tropism in TNF-0r 
induction in neonatal or adult cultures. 
To determine whether the induction oflL-1 and TNF-ci 
was  being  regulated  at  the  mlKNA  level,  Northern  blot 
analyses oflL-1 and TNF-oe mlKNA from fetal cultures be- 
fore  and  after  env  protein  stimulation  were  performed 
compared with the housekeeping cyclophilin gene.  In Fig. 
4  A, it can be seen that the negative controls, medium,  or 
W1K vaccinia virus did not induce IL-1 or TNF-cx mlKNA. 
Likewise, vPE21,  which  did not  induce  protein,  also  did 
not induce mlKNA. The positive control IFN-y/IL-1 was 
a  strong inducer  of both  cytokine mlKNAs in  either  me- 
dium  (GCT or CYTO).  For tL-1, vPE16  was a better in- 
ducer than vPE8  or vPE20,  a difference that was greater in 
CYTO  than  GCT  in  parallel with  protein  data  (Fig.  3). 
The  differences among  vPE16,  -18,  and  -20  or  between 
CYTO  and GCT  were  not as pronounced in TNF-o~ in- 
duction. 
NO Induction in Fetal Human Mix-ed Glial Cultures.  Figs. 
4  B  and  5  demonstrate  the  effects of bacterially produced 
recombinant  env  proteins  and  truncated  but  glycosylated 
recombinant env proteins expressed in HeLa cells to induce 
NO  synthase and NO￿  production  in  fetal glial cultures. 
Glial cells  produce  more  NO  in  either  GCT  or  CYTO 
media  after stimulation with  env  proteins  compared with 
the  controls  (medium  or  HIV-1  p24  for  bacterially pro- 
duced  recombinants  or  W1K  for  vaccinia  virus  recombi- 
nants).  Medium alone and HeLa  cell supernatants  gave no 
induction. With the exception of gp160 in GCT medium, 
culturing  cells in  GCT  or  CYTO  did not  influence  NO 
production.  The  NO  response  to  vPE  env  proteins  was 
lower than that to bacterially produced env proteins, which 
induced  responses  not  significantly  different  from  each 
other or the positive control IFN-y/IL-1. vPE20  and -21 
did not induce significant iNOS  or NOx-  production, in- 
dicating that the V3 loop and amino terminus ofgpl20  are 
not important (Figs. 4  B and 5). The overall pattern of NO 
response  thus  resembled  the  TNF-er  response  to  HIV-1 
env (compare Figs. 3 and 5). 
Figure 5.  NO induction in human fetal mixed glial cultures. NO~- was 
measured in supernatants from human fetal glial cells cultured with  re- 
combinant  env proteins or control  stimuli for  1 wk in  GCT  ([])  or 
CYTO ([]) modified Iscove's medium. Cells were stimulated with bacte- 
rially produced recombinant HIV-1  env proteins (gp160, gp120, gp41) 
and the control HIV-1 gag protein (p24), medium alone (MED), or IFN-3' 
plus IL-I~. The  controls for vPE recombinant envelope proteins were 
supernatants from W1K vaccinia vires-infected  (data shown) and unin- 
fected HeLa cells. HeLa cell supematants did not induce NO  (data not 
shown). Means "4- SD are shown for eight different fetal brains cultured 
and exposed to above stimuli. Except for gp160 in GCT, p24 (CYTO) vs 
gp160 (CYTO), gp120, gp41, and IFN-y/IL-1 (CYTO and GCT), P ~< 
0.001. p24  (GCT)  or MED  vs all responses, P  ~<  0.0001. Except for 
gp160, there were no significant differences between GCT and CYTO 
cultures stimulated with gp120, gp41, and IFN-~//IL-1. vPE16, -17, -8 vs 
WIK, vPE20, and vPE21, P ~< 0.0001. CYTO,  gp160, gp120, gp41, and 
IFN-"//IL-1  vs  from  vPE16, -17,  -8,  P  ~<  0.0(15. The  nmltivariate 
ANOVA and paired Student's t test analyses  were used for statistical  sig- 
nificance. 
Discussion 
This  is  the  first report  to  our  knowledge  showing  that 
envelope proteins of HIV-1  are capable of inducing cyto- 
kines and NO  in normal human glial cultures. We and oth- 
ers  have  demonstrated  NO  production  by  rat  microglia 
(13, 23, 25) and a role for TNF-0~ and NO  in white matter 
damage,  including toxicity for  oligodendrocytes and inhi- 
bition  of myelin gene  expression  (26,  27).  We  have  sug- 
gested  that  NO  may  damage  oligodendrocytes  without 
killing them.  This  is  particularly relevant  to  CNS  AIDS, 
where oligodendrocytes are only destroyed very late in dis- 
ease  (1)  but  myelin  damage  is  seen,  especially in  spinal 
cord,  even  in  the  presence  of oligodendrocytes (28).  NO 
may also be of importance in neuronal  toxicity and loss in 
CNS AIDS  (1).  Although the literature is at variance over 
how  neuronal  toxicity is  produced  in  vitro,  most  studies 
show  indirect  toxic  events  as  opposed to  direct  infection 
(29 and references therein). 
We hypothesize that IL-1, TNF-ci, and NO  production 
after  env  protein stimulation  are  interrelated and  result  in 
the gliotic pathology seen in vivo and as shown  in vitro in 
this study. In vivo in AIDS brains, astrocytes undergo glio- 
sis  because  of hypertrophy  (30);  in  these  circumstances, 
glial  fibrillary  acidic  protein  positivity  by  immunohis- 
tochemistry increases (1, 30).  IL-1, TNF-a,  and NO  cause 
a  gliotic response in both microglia and astrocytes in vitro 
(14,  31).  Thus,  we presume env proteins are indirectly in- 
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NO  may cause gliosis, we would predict little  or no other 
perceptible  toxic  effect  in  these  cultures.  We  and  others 
have shown that NO  inhibits mitochondrial function in as- 
trocytes,  but  it  does  not  kill  them.  NO  has  virtually  no 
toxic effect on microglia (23, 27). 
If the  production  of NO  in  our cultures  is the  indirect 
result  of IL-1  and TNF-cx production  or a  direct  effect of 
gp120/gp41  on NFKB, it is not clear why there is a rather 
long interval  between  IL-1  and  TNF-e~ production  (peak 
4-24 h) and peak NO production  (3-7 d). Posttranslational 
regulation ofiNOS may be an important component in the 
delay in NO production.  This is currently being examined. 
As we have suggested in these studies,  HIV-1 need not in- 
fect  glial  cells  to  contribute  to  pathology  in  the  CNS. 
While it is clear that HIV-1 infects CNS microglial cells in 
vivo, productively infected cells are rare in the brains of pe- 
diatric  AIDS patients.  The  in vivo infections  are latent  or 
defective  (1-3,  32,  33).  Even  the  culturing  of microglia 
from infected pediatric brain tissue requires 30 d before vi- 
ral replication  is readily apparent,  indicating  the  extremely 
slow  virus  life  cycle  or  poor  infectivity  leading  to  slow 
spread  of infection  (34).  In  vitro  infection  of astrocytes 
from fetal brain results in a transient, partially defective viral 
replication  (7-9).  In vivo,  astrocytes  are  not  productively 
infected  (1)  but nef protein  is expressed in a small propor- 
tion of astrocytes in pediatric AIDS brain tissues (35). A re- 
stricted  or  latent  infection  in  glia  is  therefore  thought  to 
lead to indirect but extensive neuropathogenesis. 
While several reports claim microglia in brain tissue and 
in tissue culture have CD4 on their surface (10, 34), which 
contributes  to  HIV-1  infection  (10),  many  other  studies 
have failed to detect CD4 on parenchymal microglia in fe- 
tal or adult brain from normal or HIV-l-positive brain tis- 
sue (11,  12, 36, 37), nor has CD4 been seen to be inducible 
on microglia in vitro (37). It is thought that the CD4 + cells 
in brain  are blood-derived  perivascular CNS  macrophages 
(11,  36).  Since  we  document  a  significant  number  of 
microglia  in  our  cultures  (which  are  CD4-),  either  the 
Watkins  study  (10)  and  follow-up  studies  from  the  same 
laboratory  were  demonstrating  infection  of blood-borne, 
perivascular brain macrophages and not microglia, or other 
culture  conditions  in  the  Watkins  study  allowed  for CD4 
expression and/or  infection.  The infection we achieved in 
fetal  cultures,  while  significantly  above  controls  and  on  a 
fairly  consistent  basis,  was  extremely low  compared  with 
PBL controls. The fetal tissue we used was taken during the 
second  trimester and  was therefore  older  than  that in  one 
study (11) but similar to that in another (12). Nevertheless, 
the  level of infection  in  our study was significantly lower 
than  that reported by Lee et al.  (12).  Additionally,  the  in- 
ability to infect human glia in vitro and the differences seen 
in TNF-o~, IL-1, and NO production when cells are in dif- 
ferent medium conditions suggest that the in vitro cofactors 
are not identical to in vivo cofactors, or that in vivo infec- 
tion  of glia  is  indirectly  achieved  by  fusion  of infected 
blood monocytes with brain cells. 
In summary, this  study reconfirms  two  previous  studies 
on  rat  glial  cells  demonstrating  a  functional  cytokine  re- 
sponse  to  non-CD4  epitopes  in  gp120  and  to  the  amino 
terminus ofgp41  (18,  19). IL-1, TNF-cx, and iNOS can be 
induced at the mRNA  level by env proteins and HIV-1 vi- 
rus in the absence of infection. Their production is induced 
and  regulated  differently,  given  that  media  with  different 
cofactors and  different  env domains  give different  IL-1  or 
TNF-c* responses. The responses in adult, neonatal, and fe- 
tal glial cultures are also different,  even though the  cellular 
composition of the cultures appears to be identical. The V3 
loop and carboxy terminus of gp120 and to a lesser extent 
gp41  are important for IL-1. The V3 loop of gp120  is less 
important  and  gp41  is more important  in  TNF-ot  than  in 
IL-1  induction.  While  the  macrophage-tropic  strain  of 
HIV-1  tends to be a better inducer  of cytokines,  a signifi- 
cant IL-1 and TNF-0~ response occurs with a T  cell-tropic 
strain  of HIV-1.  Further  mapping  of distinct  sequences 
within  gp120  and  gp41  that  are responsible  for TNF  and 
IL-1 production  and the role of these cytokines in NO  in- 
duction is part of the ongoing research in this lab. Elucida- 
tion of these interactions  will provide a basis for designing 
therapeutic  interventions to use in treating CNS AIDS. 
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